Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

2014-07-23 21:34:31 | BioPortfolio


P276-00 is a molecule derived from Rohitukine, which through pre clinical assays was identified as a selective Cdk4-D1 and Cdk1-B inhibitor.The inhibition of these Cdks causes cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early stage of development. It therefore has the potential for being efficacious with lesser side effects.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment






Nizam's Institute of Medicai Sciences
Andhra Pradesh




Piramal Life Sciences Limited

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:34:31-0400

Clinical Trials [28 Associated Clinical Trials listed on BioPortfolio]

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

The purpose of this study is to determine safety of P276-00 in patients with advanced multiple myeloma and whether P276-00 is effective in the treatment of advanced cases of multiple myelo...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

The purpose of this study is to determine whether P276-00 is safe and effective in treatment of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous line ...

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

The purpose of this study is to identify a dose of P276-00 that can be safely administered along with Radiation and to examine safety and efficacy of the combination in treatment of advanc...

Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression

The purpose of this study is to evaluate efficacy of P276-00 in subjects with advanced malignant melanoma positive for cyclin D1 expression

PubMed Articles [319 Associated PubMed Articles listed on BioPortfolio]

Analysis of histologic follow-up and risk of malignancy for salivary gland neoplasm of uncertain malignant potential proposed by the milan system for reporting salivary gland cytopathology.

The Milan System for Reporting Salivary Gland Cytopathology is a tiered classification scheme that includes 6 diagnostic categories. Neoplasm, which is 1 of the 6 proposed categories, consists of beni...

Blastic plasmacytoid dendritic cell neoplasm.

Blastic plasmacytoid dendritic cell neoplasm is an aggressive neoplasm with a median survival of only a few months despite treatment. An exhaustive immunohistochemical workup is required to differenti...

Biliary Mucinous Cystic Neoplasm: a Classic Presentation of a Rare Neoplasm.

Biliary mucinous cystic neoplasms are rare parenchymal neoplasms with a considerable malignant potential. Due to a lack of diagnostic imaging criteria, histopathologic evaluation remains the definitiv...

The value of grading dysplasia in appendiceal mucinous neoplasm (AMN) in the absence of pseudomyxoma peritonei.

The classification of mucinous neoplasm of the appendix is controversial. Although they lack overtly malignant features, they can be complicated by extra-appendiceal spread leading to pseudomyxoma per...

An Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm with Translocations Involving the MYC Locus Identifies t(6;8)(p21;q24) as a Recurrent Cytogenetic Abnormality.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive neoplasm with leukemic features and frequent skin involvement. Translocations involving the MYC locus have been recently identifie...

Medical and Biotech [MESH] Definitions

Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Disappearance of a neoplasm or neoplastic state without the intervention of therapy.

Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.

More From BioPortfolio on "Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms"

Quick Search


Searches Linking to this Trial